Exagen Inc (XGN)

Q: What's priced into Exagen Inc (XGN) stock?

The evidence describes XGN as cheap versus peers, while also showing a 54% premium to peers and low confidence in the valuation model. The expectations gap is negative, which suggests the market is not fully reflecting the favorable case, but valuation evidence is mixed and does not show that expectations are easy to meet.

Q: What does the Exagen Inc (XGN) outlook hinge on?

Over the next one to three years, the thesis depends on XGN delivering its 2026 revenue plan while continuing to narrow operating losses and improve cash flow. A guidance cut would weaken confidence in management’s execution; continued weakness in jobs data could weigh on cyclical healthcare businesses. Strong results and guidance from sector peers such as TMO, DHR, and NTRA would support the sector backdrop, though that is not specific evidence of XGN’s own progress.

NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-23

$7.27-2.81%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Exagen Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	18.33M
EPS	—	-0.187
FY 2026 · Annual
Revenue	$70M–$73M	73.89M
EPS	—	-0.654
FY 2027 · Annual
Revenue	—	81.32M
EPS	—	-0.499

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Improve cash flow from operations from -$10.42M in Q1	A supporting condition in Exagen Inc's published investment case. The stated target is Reduce negative cash flow toward -$3M or better.	Recovered	Cash flow worsens beyond -$10M	Cash from operations: $3.988M FY2026-Q2; GAAP. Published target: Reduce negative cash flow toward -$3M or better. Target period is not explicitly aligned with this observation. Source published Aug 4, 20263,988,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Management stated this priority in 3 of last 3 quarters. Cash and cash equivalents declined from $30 million in 2025-Q4 to $24.6 million in 2026-Q2, while cash from operations improved from negative $10.4 million in 2026-Q1 to negative $3.0 million in 2026-Q2. The trajectory shows partial progress but cash flow remains negative, indicating mixed delivery. Delivery assessment Oct 24, 2026
Operating loss improves from -$4.98M to less negative levels	Operating loss improved from -$4.98M to -$3.41M in Q1.	Improving	Operating loss worsens beyond -$5M	Operating income: $-1.722M FY2026-Q2; GAAP. Published target: Operating loss better than -$3.41M. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026-1,722,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8f7adf88-9494-40c1-bf1b-64172bf186a4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Full-year 2026 revenue between $70M and $73M	A primary condition in Exagen Inc's published investment case. The stated target is >= $70M and <= $73M.	Improving	Revenue falls below $66M in FY26	Revenue: $19.941M FY2026-Q2; GAAP. Published target: >= $70M and <= $73M. Target period is not explicitly aligned with this observation. Source published Aug 4, 202619,941,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8f7adf88-9494-40c1-bf1b-64172bf186a4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew from $15.5 million in 2025-Q1 to $19.9 million in 2026-Q2, a 29% increase. Management raised full-year 2026 revenue guidance from $70-$73 million to $72-$75 million, indicating delivery and upward trajectory on growth expectations. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.08B

$0.08B → $0.08B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$79,428,571	3 / 5
2026-07-25	Unavailable	$79,385,710	2 / 7
2026-07-26	Unavailable	$79,385,710	2 / 7
2026-07-27	Unavailable	$79,428,571	3 / 5
2026-07-28	Unavailable	$79,428,571	3 / 5
2026-07-29	Unavailable	$79,385,710	2 / 7
2026-07-30	Unavailable	$79,385,710	2 / 7
2026-07-31	Unavailable	$79,428,571	3 / 5
2026-08-01	Unavailable	$79,428,571	3 / 5
2026-08-02	Unavailable	$79,428,571	3 / 5
2026-08-03	Unavailable	$79,385,710	2 / 7
2026-08-04	Unavailable	$79,428,571	3 / 5
2026-08-05	Unavailable	$79,385,710	2 / 7
2026-08-06	Unavailable	$79,428,571	3 / 5
2026-08-08	Unavailable	$81,277,143	3 / 5
2026-08-09	Unavailable	$81,277,143	3 / 5
2026-08-10	Unavailable	$81,277,140	2 / 7
2026-08-12	Unavailable	$81,277,143	3 / 5
2026-08-13	Unavailable	$81,277,140	2 / 7
2026-08-14	Unavailable	$81,277,143	3 / 5
2026-08-15	Unavailable	$81,277,143	3 / 5
2026-08-16	Unavailable	$81,277,143	3 / 5
2026-08-17	Unavailable	$81,277,143	3 / 5
2026-08-18	Unavailable	$81,277,143	3 / 5
2026-08-19	Unavailable	$81,277,143	3 / 5
2026-08-20	Unavailable	$81,277,143	3 / 5
2026-08-21	Unavailable	$81,277,143	3 / 5
2026-08-22	Unavailable	$81,277,143	3 / 5
2026-08-23	Unavailable	$81,277,143	3 / 5
2026-08-24	Unavailable	$81,277,143	3 / 5
2026-08-25	Unavailable	$81,277,143	3 / 5
2026-08-26	Unavailable	$81,277,143	3 / 5
2026-08-27	Unavailable	$81,277,143	3 / 5
2026-08-28	Unavailable	$81,277,143	3 / 5
2026-08-29	Unavailable	$81,277,143	3 / 5
2026-08-30	Unavailable	$81,277,143	3 / 5
2026-08-31	Unavailable	$81,277,143	3 / 5
2026-09-01	Unavailable	$81,277,143	3 / 5
2026-09-02	Unavailable	$81,277,143	3 / 5
2026-09-03	Unavailable	$81,277,143	3 / 5
2026-09-04	Unavailable	$81,277,143	3 / 5
2026-09-05	Unavailable	$81,277,143	3 / 5
2026-09-06	Unavailable	$81,277,143	3 / 5
2026-09-07	Unavailable	$81,277,143	3 / 5
2026-09-08	Unavailable	$81,277,143	3 / 5
2026-09-09	Unavailable	$81,277,143	3 / 5
2026-09-10	Unavailable	$81,277,143	3 / 5
2026-09-11	Unavailable	$81,277,143	3 / 5
2026-09-12	Unavailable	$81,277,143	3 / 5
2026-09-13	Unavailable	$81,377,143	3 / 5
2026-09-14	Unavailable	$81,377,143	3 / 5
2026-09-15	Unavailable	$81,377,143	3 / 5
2026-09-16	Unavailable	$81,377,143	3 / 5
2026-09-17	Unavailable	$81,377,143	3 / 5
2026-09-18	Unavailable	$81,377,143	3 / 5
2026-09-19	Unavailable	$81,377,143	3 / 5
2026-09-20	Unavailable	$81,377,143	3 / 5
2026-09-21	Unavailable	$81,377,143	3 / 5
2026-09-22	Unavailable	$81,377,143	3 / 5
2026-09-23	Unavailable	$81,320,000	3 / 5
2026-09-24	Unavailable	$81,320,000	3 / 5
2026-09-25	Unavailable	$81,320,000	3 / 5
2026-09-26	Unavailable	$81,320,000	3 / 5
2026-09-27	Unavailable	$81,320,000	3 / 5
2026-09-28	Unavailable	$81,320,000	3 / 5
2026-09-29	Unavailable	$81,320,000	3 / 5
2026-09-30	Unavailable	$81,320,000	3 / 5
2026-10-01	Unavailable	$81,320,000	3 / 5
2026-10-02	Unavailable	$81,320,000	3 / 5
2026-10-03	Unavailable	$81,320,000	3 / 5
2026-10-04	Unavailable	$81,320,000	3 / 5
2026-10-05	Unavailable	$81,320,000	3 / 5
2026-10-06	Unavailable	$81,320,000	3 / 5
2026-10-07	Unavailable	$81,320,000	3 / 5
2026-10-08	Unavailable	$81,320,000	3 / 5
2026-10-09	Unavailable	$81,320,000	3 / 5
2026-10-10	Unavailable	$81,320,000	3 / 5
2026-10-11	Unavailable	$81,320,000	3 / 5
2026-10-12	Unavailable	$81,320,000	3 / 5
2026-10-13	Unavailable	$81,320,000	3 / 5
2026-10-14	Unavailable	$81,320,000	3 / 5
2026-10-15	Unavailable	$81,320,000	3 / 5
2026-10-16	Unavailable	$81,320,000	3 / 5
2026-10-17	Unavailable	$81,320,000	3 / 5
2026-10-18	Unavailable	$81,320,000	3 / 5
2026-10-19	Unavailable	$81,320,000	3 / 5
2026-10-20	Unavailable	$81,320,000	3 / 5
2026-10-21	Unavailable	$81,320,000	3 / 5
2026-10-22	Unavailable	$81,320,000	3 / 5
2026-10-23	Unavailable	$81,320,000	3 / 5
2026-10-24	Unavailable	$81,320,000	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	8	0	0
2026-07-01	8	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Canaccord GenuityOct 19

$11.00New observation · no comparable prior

$0$6.05$12.10

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Improve cash flow from operations from -$10.42M in Q1Cash from operations: $3.988M
Operating loss improves from -$4.98M to less negative levelsOperating income: $-1.722M
Full-year 2026 revenue between $70M and $73MRevenue: $19.941M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-77.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Exagen Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

XGN is a small, loss-making growth business with a healthcare sector tailwind, rather than a proven compounder. Its current long-term thesis is intact, supported by recent growth and raised guidance, but confidence is medium and the business still needs to show steady progress toward profitability and stronger cash generation.

What's priced into Exagen Inc

The evidence describes XGN as cheap versus peers, while also showing a 54% premium to peers and low confidence in the valuation model. The expectations gap is negative, which suggests the market is not fully reflecting the favorable case, but valuation evidence is mixed and does not show that expectations are easy to meet.

What the fundamentals likely do

Near term, revenue has risen from $15.5 million in 2025-Q1 to $19.9 million in 2026-Q2, and management raised 2026 revenue guidance to $72 million to $75 million. Operating losses have narrowed, but operating cash flow remained negative in 2026-Q2 and cash declined from 2025-Q4, so progress on profitability and cash generation is mixed. Recent earnings beats support execution, while erratic surprises and the risk of reversing guidance remain concerns.

What Exagen Inc hinges on